Amgen Inc. $AMGN is Daymark Wealth Partners LLC’s 10th Largest Position

Daymark Wealth Partners LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 152,423 shares of the medical research company’s stock after buying an additional 8,334 shares during the period. Amgen accounts for approximately 1.5% of Daymark Wealth Partners LLC’s portfolio, making the stock its 10th largest holding. Daymark Wealth Partners LLC’s holdings in Amgen were worth $43,014,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. AQR Capital Management LLC grew its stake in Amgen by 103.0% in the 1st quarter. AQR Capital Management LLC now owns 91,493 shares of the medical research company’s stock worth $28,321,000 after buying an additional 46,417 shares in the last quarter. Plancorp LLC increased its holdings in shares of Amgen by 1.4% in the 1st quarter. Plancorp LLC now owns 3,072 shares of the medical research company’s stock worth $957,000 after buying an additional 43 shares during the last quarter. UniSuper Management Pty Ltd increased its holdings in shares of Amgen by 1.1% in the 1st quarter. UniSuper Management Pty Ltd now owns 89,784 shares of the medical research company’s stock worth $27,972,000 after buying an additional 986 shares during the last quarter. Finally, Tamar Securities LLC raised its position in shares of Amgen by 15.0% during the 1st quarter. Tamar Securities LLC now owns 65,650 shares of the medical research company’s stock valued at $20,453,000 after buying an additional 8,562 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMGN. Scotiabank assumed coverage on shares of Amgen in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. Truist Financial assumed coverage on Amgen in a research note on Monday, November 24th. They set a “hold” rating and a $318.00 price target for the company. Citigroup increased their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Finally, Bank of America upped their target price on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $335.35.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 10,908 shares of company stock valued at $3,674,966 in the last quarter. Company insiders own 0.69% of the company’s stock.

Amgen Trading Up 0.1%

NASDAQ AMGN opened at $327.64 on Monday. The firm has a market cap of $176.43 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 2.98 and a beta of 0.45. Amgen Inc. has a 1-year low of $257.05 and a 1-year high of $346.38. The stock has a 50-day moving average of $326.08 and a 200-day moving average of $302.97. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the previous year, the firm earned $5.58 EPS. The business’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.